ROC analysis demonstrated that FXYD3 exhibited favorable diagnostic performance for large‐duct ICC, with a sensitivity of 81.18%, a specificity of 76.24%, and an AUC (95% CI) of 0.838 (0.788–0.887). Here, FXYD3 is linked to intrahepatic cholangiocarcinoma.